Advertisement

Gene Therapy in Nonneoplastic Lung Disease

  • Timothy Craig Allen
  • Philip T. Cagle
Part of the Molecular Pathology Library book series (MPLB, volume 1)

Abstract

The genetic basis of some nonneoplastic lung diseases and the accessibility of the pulmonary airways for administration of aerosol therapy make the concept of gene therapy for these diseases one worthy of the intense examination that it has been given.1 Cystic fibrosis (CF) and α1-antitrypsin deficiency (AATD), two common and incurable lung diseases that are caused by mutations in a single gene, have been closely investigated for potential treatment with gene therapy.1

Keywords

Gene Therapy Cystic Fibrosis Patient Airway Epithelial Cell Airway Epithelium Nonviral Vector 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davies JC, Alton E. Airway gene therapy. Adv Genet 2005;54:291–314.PubMedGoogle Scholar
  2. 2.
    Laube BL. The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care 2005;50:1161–1174.PubMedGoogle Scholar
  3. 3.
    Anson DS, Smith GJ, Parsons DW. Gene therapy for cystic fibrosis airway disease. Is clinical success imminent? Curr Gene Ther 2006;6:161–179.Google Scholar
  4. 4.
    Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995;270:18997–19007.PubMedGoogle Scholar
  5. 5.
    Davies JC. Gene and cell therapy for cystic fibrosis. Paediatr Respir Rev 2006;7S:S163–S165.Google Scholar
  6. 6.
    Lee TWR, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J 2005;387:1–15.PubMedGoogle Scholar
  7. 7.
    Drumm ML, Pope HA, Cliff WH, et al. Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell 1990;1227–1233.Google Scholar
  8. 8.
    Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trail of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003;14:1079–1088.PubMedGoogle Scholar
  9. 9.
    Goddard CA, Ratcliff R, Anderson JR, et al. A second dose of a CFTR cDNA-liposome complex is as effective as the first dose in restoring cAMP-dependent chloride secretion to null CF mice trachea. Gene Ther 1997;4:1231–1236.PubMedGoogle Scholar
  10. 10.
    Rich DP, Anderson MP, Gregory JR, et al. Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells. Nature 1990;347:358–363.PubMedGoogle Scholar
  11. 11.
    Zabner J, Ramsey BW, Meeker DP, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504–1511.PubMedGoogle Scholar
  12. 12.
    Rich DP, Couture LA, Cardoza LM, et al. Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum Gene Ther 1993;4:461–476.PubMedGoogle Scholar
  13. 13.
    Grubb BR, Pickles RJ, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994;371:8026.Google Scholar
  14. 14.
    Lei DC, Kunzelmann K, Koslowsky T, et al. Episomal expression of wild-type CFTR corrects cAMP-dependent chloride transport in respiratory epithelial cells. Gene Ther 1996;3:27–36.Google Scholar
  15. 15.
    Halbert CL, Standaert TA, Aitken ML, et al. Transduction by adeno-associated virus vectors in rabbit airway: efficiency, persistence, and readministration. J Virol 1997;71:5932–5941.PubMedGoogle Scholar
  16. 16.
    Goldman MJ, Lee PS, Yang JS, et al. Lentiviral vectors for gene therapy of cystic fibrosis. Hum Gene Ther 1997;8:2261–2268.PubMedGoogle Scholar
  17. 17.
    Wagner JA, Messner AH, Moran ML, et al. Safety and biological efficacy of an adeno-associated virus vectorcystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus. Laryngoscope 1999;109:266–274.PubMedGoogle Scholar
  18. 18.
    Jiang C, O’Connor SP, Armentano D, et al. Ability of adenovirus vectors containing different CFTR transcriptional cassettes to correct ion transport defects in CF cells. Am J Physiol 1996;271:L527–L537.PubMedGoogle Scholar
  19. 19.
    Harvey BG, Leopold PL, Hackett NR, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 1999;104:1245–1255.PubMedGoogle Scholar
  20. 20.
    Olsen JC, Johnson LG, Stutts MJ, et al. Correction of the apical membrane chloride permeability defect in polarized cystic fibrosis airway epithelia following retroviralmediated gene transfer. Hum Gene Ther 1992;3:253–266.PubMedGoogle Scholar
  21. 21.
    Johnson LG, Boyles SE, Wilson J, et al. Normalization of raised sodium absorption and raised calcium mediated chloride secretion by adenovirus-mediated expression of cystic fibrosis transmembrane conductance regulator in primary human cystic fibrosis airway epithelial cells. J Clin Invest 1995;95:1377–1382.PubMedGoogle Scholar
  22. 22.
    Noone PG, Hohneker KW, Zhou Z, et al. Safety and biological efficacy of a lipid-CFTR complex for gene transfer in the nasal epithelium of adult patients with cystic fibrosis. Mol Ther 2000;1:105–111.PubMedGoogle Scholar
  23. 23.
    Pickles RJ, Fahrner JA, Petrella JM, et al. Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer. J Virol 2000;74:6050–6057.PubMedGoogle Scholar
  24. 24.
    Ferrari S, Geddes DM, Alton EW. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv Drug Deliv Rev 2002;54:1373–1393.PubMedGoogle Scholar
  25. 25.
    Stonebreaker JR, Wagner D, Lefensty RW, et al. Glycocalyx restricts adenoviral vector access to apical receptors expressed on respiratory epithelium in vitro and in vivo: role for tethered mucins as barriers to luminal infection. J Virol 2004;78:13755–13768.Google Scholar
  26. 26.
    Greber UF, Willetts M, Webster P, et al. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 1993;75:477–486.PubMedGoogle Scholar
  27. 27.
    Pickles RJ. Physical and biological barriers to viral vectormediated delivery of genes to the airway epithelium. Proc Am Thorac Soc 2004;1:302–308.PubMedGoogle Scholar
  28. 28.
    Duan D, Yue Y, Yan Z, et al. Polarity influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epithelia. Hum Gene Ther 1998;9:2761–2776.PubMedGoogle Scholar
  29. 29.
    Summerford C, Samulski RJ. Membrane-associated heparin sulfate proteoglycan is a receptor for adenoassociated virus type 2 virions. J Virol 1998;72:1438–1445.PubMedGoogle Scholar
  30. 30.
    Houtmmeyers E, Gosselink R, Gayan-Ramirez G, et al. Regulation of mucociliary clearance in health and disease. Eur Respir J 1999;13:1177–1188.Google Scholar
  31. 31.
    Ziady AG, Davis PB. Current prospects for gene therapy of cystic fibrosis. Curr Opin Pharmacol 2006;6:1–7.Google Scholar
  32. 32.
    Driskell RA, Engelhardt JF. Current status of gene therapy for inherited lung diseases. Annu Rev Physiol 2003;65:585–612.PubMedGoogle Scholar
  33. 33.
    Weiss DJ, Pilewski JM. The status of gene therapy of cystic fibrosis. Semin Respir Crit Care Med 2003;24:749–770.PubMedGoogle Scholar
  34. 34.
    Parsons DW. Airway gene therapy and cystic fibrosis. J Paediatr Child Health 2004;41:94–96.Google Scholar
  35. 35.
    Ferrari S, Kitson C, Farley R, et al. Mucus altering agents as adjuncts to non-viral gene transfer to airway epithelium. Gene Ther 2001;8:1380–1386.PubMedGoogle Scholar
  36. 36.
    Stern M, Caplen NJ, Browning JE, et al. The effects of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther 1998;5:91–98.PubMedGoogle Scholar
  37. 37.
    Raczka E, Kukowsak-Latallo JF, Rymaszewski M, et al. The effect of synthetic surfactant Exosurf on gene transfer in mouse lung in vivo. Gene Ther 1998;5:1333–1339.PubMedGoogle Scholar
  38. 38.
    Weiss DJ, Strandjord TP, Liggitt D, et al. Perflubron enhances adenovirus-mediated gene expression in lungs of transgenic mice with chronic alveolar filling. Hum Gene Ther 1999;10:2287–2293.PubMedGoogle Scholar
  39. 39.
    Seiler MP, Luner P, Moninger TO, et al. Thixotropic solutions enhance viral-mediated gene transfer to airway epithelia. Am J Respir Cell Mol Biol. 2002;27:133–140.PubMedGoogle Scholar
  40. 40.
    Sinn PL, Shah AJ, Donovan MD, et al. Viscoelastic gel formulations enhance airway epithelial gene transfer with viral vectors. Am J Respir Cell Mol Biol 2005;32:404–410.PubMedGoogle Scholar
  41. 41.
    Johnson LG, Vanhook MK, Coyne CB, et al. Safety and efficiency of modulating paracellular permeability to enhance airway epithelial gene transfer in vivo. Hum Gene Ther 2003;14:729–747.PubMedGoogle Scholar
  42. 42.
    Bishop AE. Pulmonary epithelial stem cells. Cell Prolif 2004;37:89–96.PubMedGoogle Scholar
  43. 43.
    Parsons DW, Grubb BR, Johnson LG, et al. Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agent. Hum Gene Ther 1998;9:2661–2672.PubMedGoogle Scholar
  44. 44.
    Limberis M, Anson DS, Fuller M, et al. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002;13:1961–1970.PubMedGoogle Scholar
  45. 45.
    Koehler Dr, Frndova H, Leung K, et al. Aerosol delivery of an enhanced helper-dependent adenovirus formulation to rabbit lung using an intratracheal catheter. J Gene Med 2005;7:1409–1420.PubMedGoogle Scholar
  46. 46.
    Seidner SR, Jobe AH, Ikegami M, et al. Lysophosphatidylcholine uptake and metabolism in the adult rabbit lung. Biochim Biophys Acta 1988;961:3228–3236.Google Scholar
  47. 47.
    Croyle MA, Cheng X, Sandhu A, et al. Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. Mol Ther 2001;4:22–28.PubMedGoogle Scholar
  48. 48.
    Das A, Niven R. Use of perfluorocarbon (Fluorinert) to enhance reporter gene expression following intratracheal instillation into the lungs of Balb/c mice: implications for nebulized delivery of plasmids. J Pharm Sci 2001;90:1336–1344.PubMedGoogle Scholar
  49. 49.
    Meng ZH, Robinson D, Jenkins RG, et al. Efficient transfection of non-proliferating human airway epithelial cells with a synthetic vector system. J Gene Med 2004;6:210–221.PubMedGoogle Scholar
  50. 50.
    Scott ES, Wiseman JW, Evans MJ, et al. Enhanced gene delivery to human airway epithelial cells using an integrintargeting lipoplex. J Gene Med 2001;3125–3134.Google Scholar
  51. 51.
    Zhu N, Liggitt D, Liu Y, et al. Systemic gene expression after intravenous DNA delivery into adult mice. Science 1993;261:209–211.PubMedGoogle Scholar
  52. 52.
    Griesenbach U, Chonn A, Cassady R, et al. Comparison between intratracheal and intravenous administration intravenous administration of liposome-DNA complexes for cystic fibrosis lung gene therapy. Gene Ther 1998;5:181–188.PubMedGoogle Scholar
  53. 53.
    Koehler Dr, Hannam V, Belcastro R, et al. Targeting transgene expression for cystic fibrosis gene therapy. Mol Ther 2001;4:58–65.PubMedGoogle Scholar
  54. 54.
    Fenske DB, MacLachlan I, Cullis PR. Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 2001;3:153–158.PubMedGoogle Scholar
  55. 55.
    Niidome T, Huang L. Gene therapy progress and prospects: non-viral vectors. Gene Ther 2002;9:1647–1652.PubMedGoogle Scholar
  56. 56.
    Lechardeur D, Sohn KJ, Haardt M, et al. Metabolic instability of plasmid DNA in the cytosol: a potential barrier to gene transfer. Gene Ther 1999;6:482–497.PubMedGoogle Scholar
  57. 57.
    Grosse S, Tremeau-Bravard A, Aron Y, et al. Intracellular rate-limiting steps of gene transfer using glycosylated polylysines in cystic fibrosis airway epithelial cells. Gene Ther 2002;9:1000–1007.PubMedGoogle Scholar
  58. 58.
    Kitson C, Angel B, Judd D, et al. The extra-and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium. Gene Ther 1999;6:534–546.PubMedGoogle Scholar
  59. 59.
    Cho YW, Kim JD, Park K. Polycation gene delivery systems: escape from endosomes to cytosol. J Pharm Pharmacol 2003;55:721–734.PubMedGoogle Scholar
  60. 60.
    Snyder EL, Dowdy SF. Protein/peptide transduction domains: potential to delivery large DNA molecules into cells. Curr Opin Mol Ther 2001;3:147–152.PubMedGoogle Scholar
  61. 61.
    Munkonge FM, Hillery E, Griesenbach U, et al. Isolation of a putative nuclear import DNA shuttle protein. Mol Biol Cell 1998;9:187a.Google Scholar
  62. 62.
    Brisson M, He Y, Li S, et al. A novel T7 RNA polymerase autogene for efficient cytoplasmic expression of target genes. Gene Ther 1999;6:263–270.PubMedGoogle Scholar
  63. 63.
    Satkauskas S, Bureau MF, Puc M, et al. Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol Ther 2002;5:133–140.PubMedGoogle Scholar
  64. 64.
    Bigey P, Bureau MF, Scherman D. In vivo plasmid DNA electrotransfer. Curr Opin Biotechnol 2002;13:443–447.PubMedGoogle Scholar
  65. 65.
    Dean DA, Machado-Aranda D, Blair-Parks K, et al. Electroporation as a method for high-level non-viral gene transfer to the lung. Gene Ther 2003;10:1608–1615.PubMedGoogle Scholar
  66. 66.
    Pringle IA, Davies LA, McLachlan G, et al. Duration of reporter gene expression from naked DNA in the mouse lung following direct electroporation and development of wire electrodes for sheep lung electroporation studies. Mol Ther 2004;9:S1–S56.Google Scholar
  67. 67.
    Machado-Aranda D, Adir Y, Young JL, et al. Gene transfer of the Na+, K+-ATPase β1 subunit using electroporation increases lung liquid clearance. Am J Respir Crit Care Med 2005;171:204–211.PubMedGoogle Scholar
  68. 68.
    Machet L, Boucaud A. Phonophoresis: efficiency, mechanisms and skin tolerance. Int J Pharm 2002;243:1–115.PubMedGoogle Scholar
  69. 69.
    Miller DL, Pislaru SV, Greenleaf JE. Sonoporation: mechanical DNA delivery by ultrasonic cavitation. Somat Cell Mol Genet 2002;27:115–134.PubMedGoogle Scholar
  70. 70.
    Kim HJ, Greenleaf JF, Kinnick R, et al. Ultrasoundmediated transfection of mammalian cells. Hum Gene Ther 1996;7:1339–1346.PubMedGoogle Scholar
  71. 71.
    Manome Y, Nakamura M, Ohno T, et al. Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Hum Gene Ther 2000;11:1521–1528.PubMedGoogle Scholar
  72. 72.
    Amabile PG, Waugh JM, Lewis TN, et al. High-efficiency endovascular gene delivery via therapeutic ultrasound. J Am Coll Cardiol 2001;37:1975–1980.PubMedGoogle Scholar
  73. 73.
    Scherer F, Anton M, Schillinger U, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther 2002;9:102–109.PubMedGoogle Scholar
  74. 74.
    Gersting SW, Schillinger U, Lausier J, et al. Gene delivery to respiratory epithelial cells by magnetofection. J Gene Med 2004;6:913–922.PubMedGoogle Scholar
  75. 75.
    Gill DR, Smyth SE, Goddard CA, et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Ther 2001;8:1539–1546.PubMedGoogle Scholar
  76. 76.
    Warburton D, Wuenschell C, Flores-Delgado G, et al. Commitment and differentiation of lung cell lineages. Biochem Cell Biol 1998;76:971–995.PubMedGoogle Scholar
  77. 77.
    Yant SR, Meuse L, chu W, et al. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nature Genet 2000;25:35–41.PubMedGoogle Scholar
  78. 78.
    Hacien-Bey-Abiina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003;348:255–256.Google Scholar
  79. 79.
    Worgall S, Leopold PL, Wolff G, et al. role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther 1997;8:175–184.Google Scholar
  80. 80.
    Plank C, Mechtler K, Szoka FC Jr, et al. Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther 1996;7:1437–1446.PubMedGoogle Scholar
  81. 81.
    Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251–1254.PubMedGoogle Scholar
  82. 82.
    Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 989;245:1059–1065.Google Scholar
  83. 83.
    Hyde SC, Emsley P, Hartshorn MJ, et al. Structural model of ATP-binding proteins associated with cystic fibrosis, multidrug resistance and bacterial transport. Nature 1990;346:362–365.PubMedGoogle Scholar
  84. 84.
    Akabas MH. Cystic fibrosis transmembrane conductance regulator. Structure and function of an epithelial chloride channel. J Biol Chem 2000;275:3729–3732.PubMedGoogle Scholar
  85. 85.
    Stutts MJ, Canessa CM, Olsen JC, et al. CFTR as a cAMP-dependent regulator of sodium channels. Science 1995;269:847–850.PubMedGoogle Scholar
  86. 86.
    Metha A. CFTR: more than just a chloride channel. Pediatr Pulmonol 2005;39:292–298.Google Scholar
  87. 87.
    Kogan I, Ramjeesingh M, Li C, et al. CFTR directly mediates nucleotide-regulated glutathione flux. EMBO J 2004;1981–1989.Google Scholar
  88. 88.
    Hudson VM. New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. Treat Respir Med 2004;3:353–363.PubMedGoogle Scholar
  89. 89.
    Coakley RD, Grubb BR, Paradiso AM, et al. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. Proc Natl Acad Sci USA 2003;100:16083–16088.PubMedGoogle Scholar
  90. 90.
    Song Y, Salinas D, Nielson DW, et al. Hyperacidity of secreted fluid from submucosal glands in early cystic fibrosis. Am J Physiol Cell Physiol 2006;290:C741–C749.PubMedGoogle Scholar
  91. 91.
    Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995;310:1571–1572.PubMedGoogle Scholar
  92. 92.
    Kreda SM, Mall M, Mengos A, et al. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 2005;16:2154–2167.PubMedGoogle Scholar
  93. 93.
    Tarran R, Grubb BR, Parsons D, et al. The CF salt controversy: in vivo observations and therapeutic approaches. Mol Cell 2001;8:149–158.PubMedGoogle Scholar
  94. 94.
    Klink D, Schindelhauer D, Laner A, et al. Gene delivery systems-gene therapy vectors for cystic fibrosis. J Cystic Fibrosis 2004;3:203–212.Google Scholar
  95. 95.
    Johnson LG, Olsen JC, Sarkadi B, et al. Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet 1992;2:21–25.PubMedGoogle Scholar
  96. 96.
    Farmen SL, Karp PH, Ng P, et al. Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl-transport and overexpression can generate basolateral CFTR. Am J Physiol Lung Cell Mol Physiol 2005;289:L1123–L1130.PubMedGoogle Scholar
  97. 97.
    Boucher RC. Status of gene therapy for cystic fibrosis lung disease. J Clin Invest 1999;103:441–445.PubMedGoogle Scholar
  98. 98.
    Chu CS, Trapnell BC, Curristin SM, et al. Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest 1992;90:785–790.PubMedGoogle Scholar
  99. 99.
    Trapnell BC, Chu CS, Paakko PK, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis. Proc Natl Acad Sci USA 1991;88:6565–6569.PubMedGoogle Scholar
  100. 100.
    O’Dea S, Harrison DJ. CFTR gene transfer to lung epithelium-on the trail of a target cell. Curr Gene Ther 2002;2:173–181.PubMedGoogle Scholar
  101. 101.
    Griesenbach U, Geddes DM, Alton EWFW. Advances in cystic fibrosis gene therapy. Curr Opin Pulm Med 2004;10:542–546.PubMedGoogle Scholar
  102. 102.
    Engelhardt JF, Yankaskas JR, Ernst SA, et al. Submucosal glands are the predominant site of CFTR expression in the human bronchus. Nature Genet 1992;2:240–248.PubMedGoogle Scholar
  103. 103.
    Engelhardt JF, Zepeda M, Cohn JA, et al. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest 1994;93:737–749.PubMedGoogle Scholar
  104. 104.
    Brochiero E, Dagenais A, Prive A, et al. Evidence of a functional CFTR Cl(−) channel in adult alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2004;287:L382–L392.PubMedGoogle Scholar
  105. 105.
    Borthwick DW, Shahbazian M, Krantz QT, et al. Evidence for stem-cell niches in the tracheal epithelium. Am J Respir Cell Mol Biol 2001;24:662–670.PubMedGoogle Scholar
  106. 106.
    Hong KU, Reynolds SD, Giangreco A, et al. Clara cell secretory protein-expressing cells of the airway neuroepithelial body microenvironment include a label-retaining subset and are critical for epithelial renewal after progenitor cell depletion. Am J Respir Cell Mol Biol 2001;24:671–681.PubMedGoogle Scholar
  107. 107.
    Hong KU, Reynolds SD, Watkins S, et al. Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. Am J Pathol 2004;164:577–588.PubMedGoogle Scholar
  108. 108.
    Giangreco A, Reynolds SD, Stripp Br. Terminal bronchioles harbor a unique airway stem cell population that localizes to the bronchoalveolar duct junction. Am J Pathol 2002;161:173–182.PubMedGoogle Scholar
  109. 109.
    Reddy R, Buckley S, Doerken M, et al. Isolation of a putative progenitor subpopulation of alveolar epithelial type 2 cells. Am J Physiol Lung Cell Mol Physiol 2004;286:L658–L667.PubMedGoogle Scholar
  110. 110.
    Wang G, Bunnell BA, Painter RG, et al. Adult stem cells from bone marrow stroma differentiate into airway epithelial cells: potential therapy for cystic fibrosis. Proc Natl Acad Sci USA 2005;102:186–191.PubMedGoogle Scholar
  111. 111.
    Kotton DN, Ma BY, Cardoso WV, et al. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 2001;1128:5181–5188.Google Scholar
  112. 112.
    Krause DS, Theise ND, Collector MI, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 2001;105:369–377.PubMedGoogle Scholar
  113. 113.
    Kleeberger W, Versmold A, Rothamel T, et al. Increased chimerism of bronchial and alveolar epithelium in human lung allografts undergoing chronic injury. Am J Pathol 2003;162:1487–1494.PubMedGoogle Scholar
  114. 114.
    Gan KH, Veeze HJ, van den Ouweland AM, et al. A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 1995;333:95–99.PubMedGoogle Scholar
  115. 115.
    Cutting GR. What we have learned from correlating genotype to phenotype. Pediatr Pulmonol 2004;S27:94.Google Scholar
  116. 116.
    Alton EWFW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999;353:947–954.PubMedGoogle Scholar
  117. 117.
    Middleton PG, Geddes DM, Alton EWFW. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur Respir J 1994;7:2050–2056.PubMedGoogle Scholar
  118. 118.
    Knowles M, Gatzy J, Boucher R. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 1981;305:1489–1495.PubMedGoogle Scholar
  119. 119.
    Stern M, Munkonge FM, Caplen NJ, et al. Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects. Gene Ther 1995;2:766–774.PubMedGoogle Scholar
  120. 120.
    Caplen NJ, Alton EW, Middleton PG, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nature Med 1995;1:39–46.PubMedGoogle Scholar
  121. 121.
    Gill DR, Southern DW, Mofford KA, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:199–209.PubMedGoogle Scholar
  122. 122.
    Knowles MR, Noone PG, Hohneker K, et al. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum Gene Ther 1998;9:249–269.PubMedGoogle Scholar
  123. 123.
    Porteous DJ, Dorin JR, McLachlan GK, et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997;4:210–218.PubMedGoogle Scholar
  124. 124.
    Sorscher EJ, Logan JJ, Frizzell RA, et al. Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: a phase I trail of safety and efficacy in the nasal airway. Hum Gene Ther 1994;5:1259–1277.PubMedGoogle Scholar
  125. 125.
    Chadwick SL, Kingston HD, Stern M, et al. Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther 1997;4:937–942.PubMedGoogle Scholar
  126. 126.
    Ruiz FE, Clancy JP, Perricone MA, et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001;12:751–761.PubMedGoogle Scholar
  127. 127.
    Hyde SC, Southern KW, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000;7:1156–1165.PubMedGoogle Scholar
  128. 128.
    Konstan MW, Wagener JS, Hilliard KA, et al. Single dose escalation study to evaluate safety of nasal administration of CFTR001 gene transfer vector to subjects with cystic fibrosis. 2003;7:S386.Google Scholar
  129. 129.
    Perricone MA, Recs DD, Sacks CR, et al. Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells. Hum Gene Ther 2000;11:1997–2008.PubMedGoogle Scholar
  130. 130.
    Sanders NN, De Smedt SC, Van Rompaey E, et al. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000;162:1905–1911.PubMedGoogle Scholar
  131. 131.
    Virella-Lowell I, Poirer A, Chesnut KA, et al. Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions from cystic fibrosis patients. Gene Ther 2000;7:1783–1789.PubMedGoogle Scholar
  132. 132.
    Van Heeckeren A, Ferkol T, Tosi M. Effects of bronchopulmonary inflammation induced by pseudomonas aeruginosa on adenovirus-mediated gene transfer to airway epithelial cells in mice. Gene Ther 1998;5:345–351.PubMedGoogle Scholar
  133. 133.
    Flotte TR, Schwiebert EM, Zeitlin PL, et al. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther 2005;16:921–928.PubMedGoogle Scholar
  134. 134.
    Flotte TR. Recent developments in recombinant AAVmediated gene therapy for lung diseases. Curr Gene Ther 2005;5:361–366.PubMedGoogle Scholar
  135. 135.
    Griesenbach U, Geddes DM, Alton EW. Update on gene therapy for cystic fibrosis. Curr Opin Mol Ther 2003;5:489–494.PubMedGoogle Scholar
  136. 136.
    Ziady AG, Davis PB, Konstan MW. Non-viral gene transfer therapy for cystic fibrosis. Exp Opin Biol Ther 2003;3:449–458.Google Scholar
  137. 137.
    Zabner J, Cheng SH, Meeker D, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelial in vivo. J Clin Invest 1997;100:1529–1537.PubMedGoogle Scholar
  138. 138.
    Glasspool-Maalone J, Steenland PR, McDonald RJ, et al. DNA transfection of macaque and murine respiratory tissue is greatly enhanced by use of a nuclease inhibitor. J Gene Med 2002;4:323–332.Google Scholar
  139. 139.
    Ziady AG, Gedeon Cr, Miller T, et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003;8:936–947.PubMedGoogle Scholar
  140. 140.
    Flotte TR, Laube BL. Gene therapy in cystic fibrosis. Chest 2001;120:124S–131S.PubMedGoogle Scholar
  141. 141.
    Ferrari S, Griesenbach U, Shiraki-Iida T, et al. A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther 2004;11:1659–1664.PubMedGoogle Scholar
  142. 142.
    Zhang L, Peeples ME, Boucher RC, et al. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002;76:5654–666.PubMedGoogle Scholar
  143. 143.
    Yonemitsu Y, Kitson C, Ferrari S, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000;18:970–973.PubMedGoogle Scholar
  144. 144.
    Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005;79:1113–1124.PubMedGoogle Scholar
  145. 145.
    Griesenbach U, Boyton RJ, Somerton L, et al. Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung. Gene Ther 2006;13:449–456.PubMedGoogle Scholar
  146. 146.
    Wiseman JW, Scott ES, Shaw PA, et al. Enhancement of gene delivery to human airway epithelial cells in vitro using a peptide from the polyoma virus protein VP1. J Gene Med 2005;7:759–770.PubMedGoogle Scholar
  147. 147.
    Jenke AC, Stehle IM, Herrmann F, et al. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci USA 2004;101:11322–11327.PubMedGoogle Scholar
  148. 148.
    Glover DH, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 2005;6:299–310.PubMedGoogle Scholar
  149. 149.
    Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004;15:1255–1269.PubMedGoogle Scholar
  150. 150.
    McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004;38:819–845.PubMedGoogle Scholar
  151. 151.
    Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther 2004;11:805–810.PubMedGoogle Scholar
  152. 152.
    Schnepp BC, Jensen RL, Chen CL, et al. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol 2005;79:14793–14803.PubMedGoogle Scholar
  153. 153.
    Zhang L, Wang D, Fischer H, et al. Efficient expression of CFTR function with adeno-associated virus vectors that carry shortened CFTR genes. Proc Natl Acad Sci USA 1998;95:10158–10163.PubMedGoogle Scholar
  154. 154.
    Sirninger J, Muller C, Braag S, et al. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004;15:832–841.PubMedGoogle Scholar
  155. 155.
    Ostedgaard LS, Rokhlina T, Karp PH, et al. A shortened adeno-associated virus expression cassette for CFTR gene transfer to cystic fibrosis airway epithelia. Proc NatlAcad Sci USA 2005;102:2952–2957.Google Scholar
  156. 156.
    Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000;74:3852–3858.PubMedGoogle Scholar
  157. 157.
    Virella-Lowell I, Zusman B, Foust K, et al. Enhancing rAAV vector expression in the lung. J Gene Med 2005;7:842–850.PubMedGoogle Scholar
  158. 158.
    Walters RW, Yi SM, Keshavjee S, et al. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 2001;276:20610–20616.PubMedGoogle Scholar
  159. 159.
    Weiss DJ, Bonneau L, Allen JM, et al. Perfluorochemical liquid enhances adeno-associated virus-mediated transgene expression in lungs. Mol Ther 2000;2:624–630.PubMedGoogle Scholar
  160. 160.
    Duan D, Yue Y, Yan Z, et al. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest 2000;105:1573–1587.PubMedGoogle Scholar
  161. 161.
    Flotte TR. Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res 2005;58:1143–1147.PubMedGoogle Scholar
  162. 162.
    Conrad CK, Allen SS, Afione SA, et al. Safety of singledose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther 1996;3:658–668.PubMedGoogle Scholar
  163. 163.
    Afione SA, Conrad CK, Kearns WG, et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996;70:3235–3241.PubMedGoogle Scholar
  164. 164.
    Flotte TR, Afione SA, Zeitlin PL. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994;11:517–521.PubMedGoogle Scholar
  165. 165.
    Flotte TR, Afione SAS, Conrad C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993;90:10613–10617.PubMedGoogle Scholar
  166. 166.
    Wagner JA, Nepomuseno IB, Messner AH, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002;13:1349–1359.PubMedGoogle Scholar
  167. 167.
    Flotte TR, Brantly ML, Spencer LT, et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Hum Gene Ther 2002;13:1349–1359.PubMedGoogle Scholar
  168. 168.
    Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004;125:509–521.PubMedGoogle Scholar
  169. 169.
    Liu X, Luo M, Zhang LN, et al. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther 2005;16:1116–1123.PubMedGoogle Scholar
  170. 170.
    Halbert CL, Miller AD, McNamera S, et al. Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: implications for gene therapy using AAV vectors. Hum Gene Ther 2006;17:440–447.PubMedGoogle Scholar
  171. 171.
    Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263–267.PubMedGoogle Scholar
  172. 172.
    Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998;5:1481–1487.PubMedGoogle Scholar
  173. 173.
    Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998;4:354–357.PubMedGoogle Scholar
  174. 174.
    Copreni E, Penzo M, Carrabinio S, et al. Lentivirus-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of cystic fibrosis. Gene Ther 2004;11:S67–S75.PubMedGoogle Scholar
  175. 175.
    Kobayashi M, Iida A, Ueda Y, et al. Pseudotyped lentivirus vectors derived from simian immunodeficiency virus SIVagm with envelope glycoproteins from paramyxovirus. J Virol 2003;77:2607–2614.PubMedGoogle Scholar
  176. 176.
    Kobinger GP, Weiner DJ, Yu QC, et al. Filovirus-pseudotyped lentiviral vector can efficiently and stably transducer airway epithelia in vivo. Nat Biotechnol 2001;19:225–230.PubMedGoogle Scholar
  177. 177.
    Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther 2004;2:9.PubMedGoogle Scholar
  178. 178.
    Alton EWFW. Use of nonviral vectors for cystic fibrosis gene therapy. Proc Am Thorac Soc 2004;1:296–301.PubMedGoogle Scholar
  179. 179.
    Montier T, Delepine P, Pichon C, et al. Non-viral vectors in cystic fibrosis gene therapy: progress and challenges. Trends Biotechnol 2004;22:586–592.PubMedGoogle Scholar
  180. 180.
    Yew NS, Wang KX, Przybylska M, et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 1999;10:223–234.PubMedGoogle Scholar
  181. 181.
    Pison U, Welte T, Giersig M, et al. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006;533:341–350.PubMedGoogle Scholar
  182. 182.
    Weiss DJ. Delivery of DNA to lung airway epithelium. Methods Mol Biol 2004;246:53–68.PubMedGoogle Scholar
  183. 183.
    Kinsey BM, Densmore CL, Orson FM. Non-viral gene delivery to the lungs. Curr Gene Ther 2005;5:181–194.PubMedGoogle Scholar
  184. 184.
    Sanders NN, De Smedt SC, Cheng SH, et al. PEGylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus. Gene Ther 2002;9:363–371.PubMedGoogle Scholar
  185. 185.
    Ziady AG, Gedeon Cr, Muhammad O, et al. Minimal toxicity of stabilized compacted DNA in the murine lung. Mol Ther 2003;8:948–956.PubMedGoogle Scholar
  186. 186.
    Griesenbach U, Boyd AC. Pre-clinical endpoint assays for cystic fibrosis gene therapy. J Cystic Fibrosis 2005;4:89–100.Google Scholar
  187. 187.
    Amaral MD, Clarke LA, Ramalho AS, et al. Quantitative methods for the analysis of CFTR transcripts/splicing variants. J Cystic Fibrosis 2004;3:17–23.Google Scholar
  188. 188.
    Waterhouse JE, Harbottle RP, Keller M, et al. Synthesis and application of integrin targeting lipopeptides in targeted gene delivery. Chem Biochem 2005;6:1212–1223.Google Scholar
  189. 189.
    Stecenko AA, Brigham KL. Gene therapy progress and prospects: alpha-1-antitrypsin. Gene Ther 2003;10:95–99.PubMedGoogle Scholar
  190. 190.
    Coakley RJ, Taggart C, O’Neil S, et al. Alpha-1-antitrypsin deficiency: biological answers to clinical questions. Am J Med Sci 2001;321:33–41.PubMedGoogle Scholar
  191. 191.
    Crystal RG. The alpha 1-antitrypsin gene and its deficiency states. Trends Genet 1989;5:411–417.PubMedGoogle Scholar
  192. 192.
    Pierce JA. Alpha 1-antitrypsin augmentation therapy. Chest 1997;112:872–874.PubMedGoogle Scholar
  193. 193.
    Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha1-antitrypsin gene to the lung epithelium in vivo. Science 1991;252:431–434.PubMedGoogle Scholar
  194. 194.
    Canonico AE, Corary JT, Meyrick BO, et al. Aerosol and intravenous transfection of human alpha 1-antigrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol 1994;10:24–29.PubMedGoogle Scholar
  195. 195.
    Brigham KL, Lane KB, Meyrick B, et al. Transfection of nasal mucosa with a normal alpha 1-antitrypsin gene in alpha 1-antitrypsin deficient subjects: comparison with protein therapy. Hum Gene Ther 2000;11:1023–1032.PubMedGoogle Scholar
  196. 196.
    Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene deliver by distinct adeno-associated viral serotype vectors. Mol Ther 2000;2:619–623.PubMedGoogle Scholar
  197. 197.
    Poirier A, Campbell-Thompson M, Tang Q, et al. Toxicology and biodistribution studies of a recombinant adeno-associated virus 2-alpha-1 antitrypsin vector. Preclinica 2004;2:43–51.Google Scholar
  198. 198.
    Song S, Lu Y, Choi YK, et al. DNA-dependent PK inhibits adeno-associated virus DNA integration. Proc Natl Acad Sci USA 2004;101:2112–2116.PubMedGoogle Scholar
  199. 199.
    Song S, Laipis PJ, Berns KI, et al. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci USA 2001;98:4084–4088.PubMedGoogle Scholar
  200. 200.
    Weinacker AB, Vaszar LT. Acute respiratory distress syndrome: physiology and new management strategies. Ann Rev Med 2001;52:221–237.PubMedGoogle Scholar
  201. 201.
    Conary JT, Parker RE, Christman BW, et al. Protection of rabbit lungs from endotoxin injury by in vivo hyper-expression of the prostaglandin G/H synthase gene. J Clin Invest 1994;93:1834–1840.PubMedGoogle Scholar
  202. 202.
    Stern M, Ulrich K, Robinson C, et al. Pretreatment with cationic lipid-mediated transfer of the Na+K+-TPase pump in a mouse model in vivo augments resolution of high permeability pulmonary oedema. Gene Ther 2000;7:960–966.PubMedGoogle Scholar
  203. 203.
    Lee NA, Gelfand EW, Lee JJ. Pulmonary T cells and eosinophils: co-conspirators or independent triggers of allergic respiratory pathology? J Allergy Clin Immunol 2001;107:945–957.PubMedGoogle Scholar
  204. 204.
    Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001;107:937–944.PubMedGoogle Scholar
  205. 205.
    Lee YL, Ye L, Yu CI, et al. Construction of single-chain interleukin-12 DNA plasmid to treat airway hyperresponsiveness in an animal model of asthma. Hum Gene Ther 2001;12:2065–2079.PubMedGoogle Scholar
  206. 206.
    del Pozo V, Rojo M, Rubio ML, et al. Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene down regulation. Am J Respir Crit Care Med 2002;166:732–737.PubMedGoogle Scholar
  207. 207.
    Fonseca C, Abraham D, Black CM. Lung fibrosis. Spring Semin Immunopathol 1999;21:453–474.Google Scholar
  208. 208.
    Sime PJ, O’Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatments. Clin Immunol 2001;99:308–319.PubMedGoogle Scholar
  209. 209.
    Epperly WM, Silora CA, DeFilippi SJ, et al. Pulmonary irradiation-induced expression of VCAM-1 and ICAM-1 is decreased by manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) gene therapy. Biol Blood Marrow Transplant 2002;8:175–187.PubMedGoogle Scholar
  210. 210.
    Ziesche R, Hofbauer E, Wittmann K, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264–1269.PubMedGoogle Scholar
  211. 211.
    Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999;104:13–19.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Timothy Craig Allen
    • 1
  • Philip T. Cagle
    • 2
    • 3
  1. 1.Department of PathologyUniversity of Texas Health Center at TylerTylerUSA
  2. 2.Pathology and Laboratory MedicineWeill Medical College of Cornell UniversityNew York
  3. 3.The Methodist HospitalHoustonUSA

Personalised recommendations